WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI - News), a global technology leader in Health Sciences and Photonics, today celebrated the opening of a new Center of Excellence in Singapore. The PerkinElmer Inc. Center of Excellence in Singapore comes as part of PerkinElmer’s continued global R&D expansion efforts, and will focus on the development of new precision instrumentation and chemistries for a range of scientific and industrial laboratory applications, including drug discovery and development, environmental monitoring, food safety, and sustainable energy.
The opening of the Center of Excellence was marked earlier today by a celebration attended by employees, customers, partners and special guests. PerkinElmer global- and Singapore-based executives joined attendees at the new facility for the event, which included facility tours and a reception.
“We are pleased to establish the PerkinElmer Inc. Center of Excellence in Singapore as a base for our global R&D efforts,” said Dr. Daniel R. Marshak, vice president and chief scientific officer, PerkinElmer, Inc. “PerkinElmer is committed to growing its business globally and is making significant and long-term investments in Asia-Pacific to support the expansion of the health and environmental infrastructures of emerging growth nations. This investment in Singapore will enable us to leverage in-country expertise and resources to drive the development of new, innovative solutions to meet the changing needs of our global customers.”
The new Center of Excellence will manufacture instruments for atomic absorption spectroscopy and UV/Visable spectroscopy to detect both inorganic and organic materials in the environment, food, materials and oil industries. The new facility will also focus R&D efforts in support of the expansion of PerkinElmer’s EcoAnalytix™ solutions family. EcoAnalytix is PerkinElmer’s revolutionary problem-solving initiative that addresses the global imperatives of food and consumer product safety, water quality and sustainable energy development.
“PerkinElmer is committed to delivering world-class analytical measurement systems to help research and testing laboratories across the globe drive productivity, accuracy and quality,” said Dr. Richard F. Begley, president, Analytical Sciences, PerkinElmer, Inc. “The products that will be researched and developed here in Singapore will impact many aspects of our lives, from systems to test the safety of the water we drink and the quality of the air we breathe, to technology that may help to identify a new medication to cure a disease.”
Asia-Pacific represents a key growth region for PerkinElmer, with significant growth opportunities in areas such as pharmaceutical research, neonatal and prenatal screening, and environmental monitoring.
Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow, revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as “believes,” “intends,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our failure to introduce new products in a timely manner; (2) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (3) our failure to protect adequately our intellectual property; (4) the loss of any of our licenses or licensed rights; (5) our ability to compete effectively; (6) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (7) our ability to produce an adequate quantity of products to meet our customers’ demands; (8) our failure to maintain compliance with applicable government regulations; (9) regulatory changes; (10) our failure to comply with health care industry regulations; (11) economic, political and other risks associated with foreign operations; (12) our ability to retain key personnel; (13) restrictions in our credit agreements; (14) our ability to realize the full value of our intangible assets; and (15) other factors which we describe under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
PerkinElmer, Inc. is a global technology leader driving growth and innovation in Health Sciences and Photonics markets to improve the quality of life. The Company reported revenues of $1.8 billion in 2007, has 9,100 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.
Contact: Investor Relations: PerkinElmer, Inc. Michael A. Lawless, 781-663-5659 or Media Contact: Brodeur Worldwide Steve Marchant, 617-587-2864
Source: PerkinElmer, Inc.
